My Dashboard
Fin. Planning
Our Solutions
Stocks
Funds
Create stable, long-term investment portfolio with strong, consistent stocks.
Start Research-backed Investing ...Now.
1. Is Novartis India Ltd a good quality company?
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Novartis India Ltd is a below average quality company.
2. Is Novartis India Ltd undervalued or overvalued?
The key valuation ratios of Novartis India Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
3. Is Novartis India Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Novartis India Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘValue Creation Index Colour Code Guide ⓘ |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |||
| ROCE % ⓘ | 10.7% | 7.6% | 18.1% | 5.4% | 8.3% | 4.5% | 2.2% | 3.2% | 4.9% | 14.3% | - | ||
| Value Creation Index ⓘ | -0.2 | -0.5 | 0.3 | -0.6 | -0.4 | -0.7 | -0.9 | -0.8 | -0.7 | 0.0 | - | ||
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ |
|||||||||||||
| Sales ⓘ | 862 | 873 | 690 | 656 | 564 | 491 | 438 | 381 | 400 | 379 | 348 | ||
| YoY Gr. Rt. % | - | 1.3% | -21% | -4.9% | -14.1% | -13% | -10.7% | -13% | 4.9% | -5.3% | - | ||
| Adj EPS ⓘ | 31 | 23.2 | 62.1 | 20.2 | 26.2 | 13.3 | 4.6 | 7.2 | 12.6 | 42.1 | 28.9 | ||
| YoY Gr. Rt. % | - | -25.2% | 167.6% | -67.5% | 29.8% | -49.4% | -65% | 55.2% | 74.6% | 234.8% | - | ||
| BVPS (₹) ⓘ | 300.8 | 313.5 | 375.6 | 329.5 | 299.8 | 309.3 | 293.4 | 289.4 | 281.2 | 314.3 | 322.4 | ||
| Adj Net Profit ⓘ | 99.2 | 74.2 | 199 | 56.8 | 64.7 | 32.7 | 11.5 | 17.8 | 31 | 104 | 71 | ||
| Cash Flow from Ops. ⓘ | -4.6 | -59.6 | 56.6 | -40.8 | 161 | -194 | -23.1 | -69.2 | 38.7 | 44.8 | - | ||
| Debt/CF from Ops. ⓘ | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||
CAGR ⓘCAGR Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 Years | 5 Years | 3 Years | 1 Years | |||||||||
| Sales ⓘ | -8.7% | -7.7% | -4.8% | -5.3% | ||||||||
| Adj EPS ⓘ | 3.5% | 10% | 108.6% | 234.8% | ||||||||
| BVPSⓘ | 0.5% | 1% | 2.3% | 11.8% | ||||||||
| Share Price | 6.3% | -0.8% | 5% | 4.8% | ||||||||
Key Financial Parameters ⓘPerformance Ratio Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | ||
| Return on Equity % ⓘ | 10.7 | 7.6 | 18.1 | 5.4 | 7.8 | 4.4 | 1.6 | 2.5 | 4.4 | 14.2 | 9.1 | |
| Op. Profit Mgn % ⓘ | -0.2 | -0.9 | 4.6 | 3.7 | -1.4 | 3.2 | 3.1 | 6.8 | 6.7 | 17.5 | 14.5 | |
| Net Profit Mgn % ⓘ | 11.5 | 8.5 | 28.8 | 8.7 | 11.5 | 6.7 | 2.6 | 4.7 | 7.8 | 27.4 | 20.5 | |
| Debt to Equity ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | |
| Working Cap Days ⓘ | 819 | 667 | 398 | 429 | 688 | 844 | 675 | 891 | 1,164 | 1,169 | 0 | |
| Cash Conv. Cycle ⓘ | 25 | 29 | 30 | 26 | -7 | -20 | -5 | 4 | 8 | -8 | 0 | |
Return on Equity has increased versus last 3 years average to 9.10%
Net Profit is growing at healthy rate in last 3 years 108.55%
Sales growth has been subdued in last 3 years -4.75%
Sales growth is not so good in last 4 quarters at -17.37%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 28.9 | - |
| TTM Sales (₹ Cr.) | 348 | - |
| BVPS (₹.) ⓘ | 322.4 | - |
| Reserves (₹ Cr.) ⓘ | 784 | - |
| P/BV ⓘ | 2.21 | - |
| PE ⓘ | 24.72 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 554.00 / 909.00 |
| All Time Low / High (₹) | 65.00 / 1436.35 |
| Market Cap (₹ Cr.) | 1,761 |
| Equity (₹ Cr.) | 12.4 |
| Face Value (₹) | 5 |
| Industry PE ⓘ | 60.2 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Novartis was created in 1996 through a merger of Ciba-Geigy and Sandoz. Novartis and its predecessor companies trace roots back more than 250 years, with a rich history of developing innovative products. From beginnings in the production of synthetic fabric dyes, the companies that eventually became Novartis branched out into producing chemicals and ultimately pharmaceuticals.
The history of Novartis traces the converging destinies of three companies: Geigy, a chemicals and dyes trading company founded in Basel, Switzerland in the middle of the 18th century; Ciba, which began producing dyes in 1859; and Sandoz, a chemical company founded in Basel in 1886.
These companies shared a common trait which lives on at Novartis: a passion for developing and marketing new products that contribute to human progress through advances in science and health. Building on this heritage, today Novartis focuses its innovation prowess on addressing the unmet needs of patients worldwide.
Since 1947, Novartis has had a significant footprint in India - committed to drug development, manufacturing, commercial and social business services. It has three legal entities namely, Novartis Healthcare Private Limited, Novartis India Limited and Sandoz Private Limited employing thousands of people. It has a rich portfolio of both innovative and established medicines addressing various therapeutic needs: cardiovascular, eye care, immunology and dermatology, metabolics, neuroscience, oncology, respiratory and organ transplant, to meet the medical needs of patients in India.
Its social business -- Arogya Parivar -- is expanding access to community education, improved infrastructure and affordable healthcare products for underserved populations in rural India.
The company’s purpose is to reimagine medicine to improve and extend people’s lives. It uses innovative science and technology to address some of society’s most challenging healthcare issues. It discover and develops breakthrough treatments and find new ways to deliver them to as many people as possible. It also aims to reward those who invest their money, time and ideas in the company.
Business area of the company
As a science-based and patient-oriented healthcare company, it strives to be a global leader in growing areas of healthcare. Following a corporate transformation Novartis globally is focused on three divisions with global scale and innovation power - pharmaceuticals, eye care and generic medicines. This has strengthened the future growth prospects of the company.
In India, the Pharmaceutical business of Novartis India Limited is focused on Bone & Pain, Calcium portfolio, Gynecology and Neurosciences and the Generics business is focused on Gynecology, Anti-TB and Anti-infectives.
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Download APP
